CTNM Stock Summary and Trading Ideas (Contineum Therapeutics | NASDAQ:CTNM)

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

What symbol and exchange does Contineum Therapeutics shares trade?

Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.

What is Contineum Therapeutics stock price doing today?

As of April 17, 2026, CTNM stock price climbed to $13.53 with 419,326 million shares trading.

What is Contineum Therapeutics's Beta?

CTNM has a beta of -0.85, meaning it tends to be less sensitive to market movements. CTNM has a correlation of 0.03 to the broad based SPY ETF.

How much is Contineum Therapeutics worth?

CTNM has a market cap of $494.24 million. This is considered a Small Cap stock.

How much money does Contineum Therapeutics make?

Last quarter Contineum Therapeutics reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.06.

What are the top ETFs holding Contineum Therapeutics?

The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, VXF, IBB, SCHA, IWC.

Is Contineum Therapeutics (CTNM) a good investment?

CTNM has outperformed the market in the last year with a return of +192.9%, while the SPY ETF gained +36.3%. In the last 3 month period, CTNM beat the market returning +15.2%, while SPY returned +2.9%. However, in the most recent 2 weeks CTNM has underperformed the stock market by returning +0.7%, while SPY returned +8.3%.

What are the support and resistance levels for Contineum Therapeutics (CTNM)?

CTNM support price is $12.62 and resistance is $13.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.